Narmada Gelatines Ltd Downgraded to Buy Amid Expensive Valuation and Strong Financials

Quality Assessment: Sustained Operational Excellence

Narmada Gelatines continues to demonstrate high-quality fundamentals, underpinned by strong management efficiency and consistent profitability. The company reported a return on capital employed (ROCE) of 25.78% in the latest period, with a return on equity (ROE) of 20.13%, signalling effective utilisation of shareholder funds. These figures are supported by a low average debt-to-equity ratio of 0.03 times, indicating a conservative capital structure that minimises financial risk.

Operationally, the firm has posted a remarkable 44.69% annual growth rate in operating profit, with the latest quarter (Q4 FY25-26) delivering a 29.66% increase in operating profit. The operating profit margin to net sales reached a peak of 22.30%, reflecting strong pricing power and cost control. Additionally, the company has declared positive results for three consecutive quarters, reinforcing its earnings stability and growth trajectory.

Valuation: Elevated Premium Triggers Downgrade

The primary catalyst for the downgrade lies in the valuation parameters, which have shifted from fair to expensive territory. Narmada Gelatines now trades at a price-to-earnings (PE) ratio of 10.41, which, while moderate in absolute terms, is considered expensive relative to its historical valuation and peer group. The price-to-book (P/B) value stands at 2.32, signalling a premium over the company’s net asset value.

Enterprise value multiples also reflect this premium: EV to EBIT is 8.73, EV to EBITDA is 8.12, and EV to capital employed is 2.25. These multiples are higher than many peers in the Specialty Chemicals sector, such as J.G. Chemicals (PE 32.16, EV/EBITDA 23.65) and Titan Biotech (PE 55.17, EV/EBITDA 42.80), but the downgrade is driven by the relative shift in Narmada’s own valuation grade from fair to expensive.

Despite a low PEG ratio of 0.18, which typically indicates undervaluation relative to growth, the market appears to have priced in significant future expectations, limiting further upside from a valuation standpoint. This premium valuation has prompted a more cautious stance from analysts, resulting in the rating adjustment.

Financial Trend: Robust Growth and Profitability

The financial trend for Narmada Gelatines remains very positive, with the company delivering strong quarterly and annual results. The latest quarter saw the highest quarterly PBDIT at ₹13.76 crores, while the half-year ROCE peaked at 26.28%. Operating profit growth of 29.66% in the most recent quarter underscores the company’s ability to expand margins and scale operations effectively.

Long-term returns have been impressive, with the stock generating a 59.24% return over the past year, significantly outperforming the BSE500 index return of 4.19%. Over five and ten years, the stock has delivered cumulative returns of 173.70% and 265.49% respectively, well ahead of the Sensex benchmarks. This market-beating performance reflects the company’s strong fundamentals and investor confidence.

However, the 3-year return of 8.61% trails the Sensex’s 19.64%, suggesting some periods of relative underperformance. This mixed trend highlights the importance of monitoring ongoing financial momentum alongside valuation considerations.

Technicals: Positive Momentum Amidst Volatility

From a technical perspective, Narmada Gelatines has shown resilience and upward momentum. The stock closed at ₹541.65 on 12 Aug 2026, up 2.74% from the previous close of ₹527.20. It touched a 52-week high of ₹545.00 on the same day, indicating strong buying interest near the peak price levels.

Price action over the short term has been encouraging, with a one-week return of 9.15% and a one-month gain of 5.16%, both outperforming the Sensex’s negative and modest positive returns respectively. This suggests that technical indicators remain supportive despite the valuation concerns.

Nevertheless, the stock’s micro-cap status and premium valuation may introduce volatility, requiring investors to weigh technical strength against fundamental risks carefully.

Peer Comparison and Industry Context

Within the Specialty Chemicals sector, Narmada Gelatines’ valuation remains elevated compared to several peers. For instance, J.G. Chemicals trades at a PE of 32.16 and EV/EBITDA of 23.65, while Titan Biotech is valued at a PE of 55.17 and EV/EBITDA of 42.80. Despite these higher multiples, Narmada’s downgrade stems from its own valuation grade shifting from fair to expensive, reflecting a relative premium that may limit near-term upside.

Other competitors such as Nitta Gelatin and DCW also carry expensive valuations, but Narmada’s strong financial metrics and low leverage provide a cushion against sector volatility. The company’s dividend yield of 1.85% adds to its appeal for income-focused investors, complementing its growth profile.

Risks and Considerations

Investors should be mindful of the risks associated with the company’s premium valuation and micro-cap status. The price-to-book ratio of 2.32 indicates that the stock is trading at more than twice its net asset value, which may expose it to valuation corrections if growth expectations are not met. Additionally, while the PEG ratio of 0.18 suggests undervaluation relative to earnings growth, it also implies that the market has already priced in significant expansion.

Market volatility and sector-specific headwinds could impact the stock’s performance, especially given its relatively limited liquidity. However, the company’s strong financial trend, low debt, and consistent profitability provide a solid foundation for long-term investors willing to tolerate valuation risk.

Conclusion: Balanced Outlook with Cautious Optimism

The downgrade of Narmada Gelatines Ltd’s investment rating from Strong Buy to Buy reflects a balanced reassessment of its valuation and fundamentals. While the company continues to deliver robust financial results, operational efficiency, and market-beating returns, its elevated valuation metrics warrant a more cautious stance. Investors are advised to consider the company’s strong growth prospects alongside the premium pricing and potential volatility inherent in micro-cap stocks.

Overall, Narmada Gelatines remains a compelling investment within the Specialty Chemicals sector, but the revised rating signals the need for careful monitoring of valuation trends and market conditions going forward.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today